These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837 [TBL] [Abstract][Full Text] [Related]
5. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. Tashkin DP; Pearle J; Iezzoni D; Varghese ST COPD; 2009 Feb; 6(1):17-25. PubMed ID: 19229704 [TBL] [Abstract][Full Text] [Related]
6. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use. Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347 [TBL] [Abstract][Full Text] [Related]
7. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Donohue JF; Fogarty C; Lötvall J; Mahler DA; Worth H; Yorgancioglu A; Iqbal A; Swales J; Owen R; Higgins M; Kramer B; Am J Respir Crit Care Med; 2010 Jul; 182(2):155-62. PubMed ID: 20463178 [TBL] [Abstract][Full Text] [Related]
8. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial. Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K; Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473 [TBL] [Abstract][Full Text] [Related]
9. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Tashkin DP; Donohue JF; Mahler DA; Huang H; Goodwin E; Schaefer K; Hanrahan JP; Andrews WT Respir Med; 2009 Apr; 103(4):516-24. PubMed ID: 19208459 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371 [TBL] [Abstract][Full Text] [Related]
12. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Hanania NA; Crater GD; Morris AN; Emmett AH; O'Dell DM; Niewoehner DE Respir Med; 2012 Jan; 106(1):91-101. PubMed ID: 22040533 [TBL] [Abstract][Full Text] [Related]
13. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Keam SJ; Keating GM Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163 [TBL] [Abstract][Full Text] [Related]
14. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Donohue JF; Hanania NA; Fogarty C; Campbell SC; Rinehart M; Denis-Mize K Ther Adv Respir Dis; 2008 Aug; 2(4):199-208. PubMed ID: 19124372 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Gross NJ; Nelson HS; Lapidus RJ; Dunn L; Lynn L; Rinehart M; Denis-Mize K; Respir Med; 2008 Feb; 102(2):189-97. PubMed ID: 18363201 [TBL] [Abstract][Full Text] [Related]
16. Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI. Sutherland ER; Brazinsky S; Feldman G; McGinty J; Tomlinson L; Denis-Mize K Curr Med Res Opin; 2009 Mar; 25(3):653-61. PubMed ID: 19232039 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study. Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130 [TBL] [Abstract][Full Text] [Related]
19. Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD. Ichinose M; Seyama K; Nishimura M; Fukuchi Y; Nagai A; Mishima M; Kubo K; Respir Med; 2010 Feb; 104(2):267-74. PubMed ID: 19875277 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Zhong N; Zheng J; Wen F; Yang L; Chen P; Xiu Q; Yao W; Sun T; Zhao Z; Shen H; Shi Y; Lin J; Li Q Curr Med Res Opin; 2012 Feb; 28(2):257-65. PubMed ID: 22046961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]